MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: A meta-analysis is a quantitative, formal study design in epidemiology and clinical medicine that systematically integrates and quantitatively synthesizes findings from multiple independent studies. This approach not only enhances statistical power but also enables the exploration of effects across diverse populations and helps resolve controversies arising from conflicting studies. Objective: This study aims to develop and implement a user-friendly tool for conducting meta-analyses, addressing the need for an accessible platform that simplifies the complex statistical procedures required for evidence synthesis while maintaining methodological rigor. Methods: The platform available at MetaAnalysisOnline.com enables comprehensive meta-analyses through an intuitive web interface, requiring no programming expertise or command-line operations. The system accommodates diverse data types including binary (total and event numbers), continuous (mean and SD), and time-to-event data (hazard rates with CIs), while implementing both fixed-effect and random-effect models using established statistical approaches such as DerSimonian-Laird, Mantel-Haenszel, and inverse variance methods for effect size estimation and heterogeneity assessment. Results: In addition to statistical tests, graphical representations including the forest plot, the funnel plot, and the z score plot can be drawn. A forest plot is highly effective in illustrating heterogeneity and pooled results. The risk of publication bias can be revealed by a funnel plot. A z score plot provides a visual assessment of whether more research is needed to establish a reliable conclusion. All the discussed models and visualization options are integrated into the registration-free web-based portal. Leveraging MetaAnalysisOnline.com's capabilities, we examined treatment-related adverse events in patients with cancer receiving perioperative anti–PD-1 immunotherapy through a systematic review encompassing 10 studies with 8099 total participants. Meta-analysis revealed that anti–PD-1 therapy doubled the risk of adverse events (risk ratio 2.15, 95% CI 1.39-3.32), with significant between-study heterogeneity (I2=95%) and publication bias detected through the Egger test (P=.02). While these findings suggest increased toxicity associated with anti–PD-1 treatment, the z score analysis indicated that additional studies are needed for definitive conclusions. Conclusions: In summary, the web-based tool aims to bridge the void for clinical and life science researchers by offering a user-friendly alternative for the swift and reproducible meta-analysis of clinical and epidemiological trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing heterogeneity in meta-analysis: Q statistic or I² index?
Huedo-Medina, T. B., Sánchez-Meca, J., Marín-Martínez, F., & Botella, J. (2006) · Psychological Methods · doi:10.1037/1082-989x.11.2.193 · Cited by 4,256 · cited 1×
“One of its advantages lies in the ease of interpreting its results: I 2 percentages of 25% correspond to low, 50% to medium, and 75% to high levels of heterogeneity, respectively [12].”
Interpretation of random effects meta-analyses
Riley, R. D., Higgins, J. P. T., & Deeks, J. J. (2011) · BMJ · doi:10.1136/bmj.d549 · Cited by 2,884 · cited 1×
“The plot also includes the prediction interval, which is widely used to express the amount of heterogeneity in a meta-analysis [29].”
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112651 · Cited by 1,274
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180 · cited 1×
“Altogether 10 studies were included with a total of 4379 participants in the anti–PD-1–treated cohort and 3720 participants in the control cohort [17-26].”
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034442 · Cited by 1,065
Sterne, J. A. C., & Harbord, R. M. (2004) · The Stata Journal: Promoting communications on statistics and Stata · doi:10.1177/1536867x0400400204 · Cited by 708
Takeshima, N., Sozu, T., Tajika, A., Ogawa, Y., Hayasaka, Y., & Furukawa, T. A. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-30 · Cited by 387 · cited 1×
“…the results can be challenging due to the need to categorize the SMD. Typically, we use the categories outlined by Cohen, which indicate that an SMD of approximately 0.2 corresponds to a small effect, around 0.5 signifies a moderate effect, and approximately 0.8 indicates a large effect [15].”
InfluentialForest plots in reports of systematic reviews: a cross-sectional study reviewing current practice
Schriger, D. L., Altman, D. G., Vetter, J. A., Heafner, T., & Moher, D. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyp370 · Cited by 87 · cited 1×
“Certain formats were not optimal for information exchange, and a significant number of plots contained insufficient data to be considered useful [30].”
Cited by
VidyaRaj, C. K., Vadakunnel, M. J., Mani, B. R., Anbazhagi, M., Pradhabane, G., Venkateswari, R., Palavesam, S., Venkatesh, K., Usharani, B., Sriramkumar, S. R., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92613-5 · Cited by 31
Metadata
- Authors
- Fekete, J. T., & Győrffy, B.
- Venue
- Journal of Medical Internet Research
- Publisher
- JMIR Publications Inc.
- Published
- 2025-03-06
- Volume
- 27
- Pages
- e64016
- ISSN
- 1438-8871 (ISSN-L)
- OpenAlex
- W4407319703
- Cited by
- 221
- References
- 10
- FWCI
- 58.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies. https://app.cochat.ai/papers/10.2196/64016
- The paper
- Fekete, J. T., & Győrffy, B. (2025). MetaAnalysisOnline.com: Web-Based Tool for the Rapid Meta-Analysis of Clinical and Epidemiological Studies. Journal of Medical Internet Research. https://doi.org/10.2196/64016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.